F2R and myocardial infarction: Vorapaxar, a competitive and selective antagonist of thrombin receptor PAR-1, was assessed in Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events–Thrombolysis in Myocardial Infarction 50 (TRA 2°P–TIMI 50) trial, where vorapaxar 2.5 mg daily was compared against placebo on top of standard therapy (e.g., aspirin or clopidogrel) in the secondary prevention of patients with a history of MI, IS or PAD [65].